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Abstract
Background: Patients with multiple sclerosis (MS) are at increased risk of osteoporosis and fractures. Adipose tissue-derived
adipokines may play important roles in the osteoimmunology of MS. In order to determine whether omentin-1 and vaspin
may be related to bone health in MS patients, we compared circulating levels of these recently identified adipokines,
between MS patients and healthy controls.
Methods: A total of 35 ambulatory MS patients with relapsing-remitting courses were compared with 38 age- and sex-
matched healthy controls. Bone mineral density (BMD) was determined for the lumbar spine (L2–L4) and the proximal femur
using dual-energy x-ray absorptiometry. Circulating omentin-1, vaspin, osteocalcin, osteopontin, osteoprotegerin, the
receptor activator of nuclear factor-kB ligand, matrix metalloproteinase 9, C-reactive protein and 25-hydroxy vitamin D
levels were evaluated by highly specific enzyme-linked immunosorbent assay methods.
Results: There was no significant difference between the two groups regarding bone-related cytokines, adipocytokines, and
the BMD measurements of patients with MS and the healthy controls. However, in multiple regression analysis, serum
omentin-1 levels were positively correlated with BMD at the femoral neck (b=0.49, p=0.016), total hip (b=0.42, p=0.035),
osteopontin (b=0.42, p=0.030) and osteocalcin (b=0.53, p=0.004) in MS patients. No correlations were found between
vaspin, biochemical, and BMD measures in both groups.
Conclusions: Elevated omentin-1 serum levels are correlated with BMD at the femoral neck and the serum levels of
osteocalcin and osteopontin in MS patients. Therefore, there is crosstalk between adipose tissue and bone in MS.
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Introduction
Adipose tissue can now be considered a true endocrine organ
that secrets adipokines, which are protein factors that show a
number of important systemic complex interactions and influence
a large number of different organ systems [1].
For the past 15 years, clinical observations and scientific
evidence have revealed that adipokines play important roles in the
crosstalk between bone and energy metabolisms [2]. The leptin-
dependent central control of bone mass [3] and adiponectin-
induced osteoblast differentiation and increasing osteoclast
formation [4] suggest that adipocyte tissue-derived factors—
adipokines—affect bone remodeling. However, although the
relationship of leptin, adiponectin, resistin and visfatin with
chondrocyte function and the skeleton have been investigated,
the role of novel adipokines (e.g., omentin-1 and vaspin) in bone
biology remains to be elucidated.
Omentin-1 is a novel 34 kDa adipokine that is highly and
selectively expressed in visceral adipose tissue compared with
subcutaneous adipose tissue [5,6]. Furthermore, omentin-1
enhances insulin action and Akt phosphorylation [6]; it is inversely
related to obesity [7] and is downregulated by insulin and glucose
[8]. An increase in this novel adipokine concentration with an
increase of insulin sensitivity after weight loss was reported [9].
Vaspin (visceral adipose tissue-derived serpin), as a member of
the serine protease inhibitor family, is also a novel adipocytokine
with insulin-sensitizing effects [10]. Circulating levels and tissue
expression of vaspin increased at the peak of obesity and insulin
resistance in Otsuka Long-Evans Tokushima fatty rats, an animal
model of abdominal obesity and type 2 diabetes mellitus [11].
PLoS ONE | www.plosone.org 1 September 2011 | Volume 6 | Issue 9 | e24240Adipokines also influence immune responses. Indeed, strong
evidence suggests that complex interactions exist among adipo-
kines and inflammatory and autoimmune diseases. The study of
leptin has shown that this adipocyte-derived hormone plays a
major role in the immune response in normal and pathophysio-
logical processes, including inflammation, rheumatic diseases, and
autoimmune conditions [12–15]. Hence, leptin may contribute to
the pathogenecity of immune-mediated disorders such as MS [16].
It has been shown that leptin-deficient mice were resistant to
experimental autoimmune encephalomyelitis, an animal model of
human MS [17] and that this adipokine can affect the survival and
proliferation of autoreactive CD4(+) T cells in experimental
autoimmune encephalomyelitis [18].
The aims of this study are: 1) to compare circulating levels of
omentin and vaspin, which are recently identified adipokines,
between MS patients and healthy controls; 2) to correlate these
adipokine levels with bone mineral density (BMD) and bone-
related mediators and cytokines in order to determine whether
circulating levels of these novel cytokines may be related to bone
health in MS patients.
Materials and Methods
Patients and controls
Thirty-five consecutive definite MS patients (mean age6SD
31.5767.26 years: 27 women and 8 men) with relapsing-remitting
courses were prospectively enrolled in the study at the neurology
clinic of Bushehr University of Medical Sciences. All patients were
diagnosed according to McDonald’s criteria [19]. The Kurtzke
Expanded Disability Status Scale (EDSS) was used to score degree
of disability [20]. None of the patients had immobility, had been
formerly diagnosed with any bone disease, had been administered
curative medication for osteoporosis, or were in menopause.
The age and sex-matched controls (30.066.12 years: 30 women
and 8 men) were selected from a cohort of healthy subjects
recruited by the Persian Gulf nuclear medicine research center at
Bushehr University of Medical Sciences for evaluation of bone
health in the Persian Gulf region.
The following exclusion criteria were used for MS patients and
the healthy controls: 1) the known presence of generalized bone
diseases including hyperparathyroidism, hypoparathyroidism,
thyroid disorders, rheumatoid arthritis, Cushing disease, steroid-
induced osteoporosis, renal osteodystrophy, and other metabolic
diseases; 2) a history of malignant diseases and liver diseases; 3)
drug addiction; and 4) restriction to bed rest within the last 2 weeks
after an illness or complete bed rest for 3 months.
All subjects completed a detailed questionnaire that requested
demographic and behavioral information as well as a medical
history of conditions that could influence bone mass and
metabolism. Venous blood was obtained from all patients and
healthy controls in a fasting state. All the sera were kept frozen at
270 C until they were used.
The study was approved by the medical-ethical committee of
Bushehr University of Medical Sciences, and written informed
consent was obtained from all subjects.
Measurements
Physical measurements. A stadiometer was used to
measure height and weight. Heavy outer garments and shoes
were removed before the participants’ height and weight were
measured. Body mass index (BMI) was calculated.
BMD was determined for the lumbar spine (L2–L4) and
proximal femur (neck) using dual-energy x-ray absorptiometry on
an Osteocore II bone densitometer (Osteocore II discrepancies,
the same operator tested all the women during the study.
Duplicate measurements were obtained from 30 women who
agreed to undergo a repeat assessment on the same day, and the
precision errors were calculated using the root mean square
method. The coefficients of variation (CVs; precision) of
measurements of the lumbar spine and femoral neck were 0.8%
and 1.6%, respectively.
Laboratory measurements. Measurement of C-reactive
protein by a CRP high sensitive enzyme-linked immunosorbent
assay (hs-CRP ELISA; IBL International, GmbH, Hamburg,
Germany) was conducted. The detectable concentration of the
CRP HS ELISA assay was estimated to be 0.02 mg/ml. The mean
intraassay and interassay CVs of the CRP assay were 4.1% to 6%
and 5.8% to 6.3%, respectively.
An enzyme immunoassay (EIA) kit (Immundiagnostik, Ben-
sheim and Biomedica, Wien) was used for measurement of 25-
hydroxy vitamin D (25-OH vitamin D). The detection limit of the
assay was 5.6 nmol/l. The mean intraassay and interassay CVs of
the 25-OH vitamin D assay were 10.7% and 11.8% to 13.2%,
respectively.
Serum OPG levels were measured using an ELISA commercial
kit (Biomedica Gruppe, Vienna, Austria). The detection limit of
the assay was 0.14 pmol/l. The mean intraassay and interassay
CVs of the OPG assay were 4% to 10% and 7% to 8%,
respectively.
RANKL levels were measured using an ELISA kit with an
additional enhancement system (ampli-sRANKL; Biomedica
Gruppe). The detection limit of the assay was 0.4 pg/mL. The
mean intra-assay and interassay CVs of the RANKL assay were
8% to 9% and 6% to 3%, respectively.
The N-MID Osteocalcin ELISA (Nordic Bioscience Diagnostics
A/S) was used for the quantitative measurement of osteocalcin in
sera. The intra-assay CVs for the low (7.0 ng/mL), medium
(21.8 ng/mL), and high (43.2 ng/mL) values were 3.4%, 2.0%,
and 2.4%, respectively.
For the detection of osteopontin and matrix metalloproteinase 9
(MMP-9) in samples, commercially available ELISA (Quantikine,
R&D Systems, Minneapolis, USA) kits were used according to the
manufacturer’s instructions. The mean minimum detectable dose
of osteopontin was 0.011 ng/ml, with an intra-assay coefficient of
variation of 4.0% and an interassay coefficient of variation of
6.6%. The mean minimum detectable dose of MMP-9 was
0.013 ng/ml, with an intra-assay coefficient of variation of 4.1%
and an interassay coefficient of variation of 7.6%.
To detect vaspin in the serum samples, commercially (Cat. No.
Cat. No. V0712EK) available enzyme-linked immunosorbent
assay kits (AdipoGen, Seoul, Korea) were used according to the
manufacturer’s instructions. The assay sensitivity for vaspin was
0.012 ng/ml; the intra- and interassay coefficients of variance
were 1.3% to 3.8% and 3.3% to 9.1%, respectively.
Serum omentin-1 concentrations were measured using manual
omentin-1 (human) detection (ELISA kit [intelectin-1 (human)
ELISA kit, Apotech Corporation, Switzerland]). The detection
limit of the assay was 0.4 ng/ml (range 0.5 to 32 ng/ml). The
mean intraassay and interassay CVs of the omentin-1 assay were
4.51% to 7.4% and 4.19% to 9.27%, respectively. The antibodies
used in this kit are specific to measurement of natural and
recombinant human omentin-1.
Statistical Analysis
Normal distribution of the data was controlled with the
Kolmogorov-Smirnov test. Probability values ,5% were consid-
ered statistically significant. The significance of the difference in
the results between the two groups was determined with chi-square
Omentin-1 in Multiple Sclerosis
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to compare the values across groups in the presence of a normal
distribution. Significant differences were assessed with the Mann-
Whitney U test in the absence of a normal distribution.
Multiple linear regression models were used to assess the
association between omentin-1 (independent variable) and BMD
at a number of skeletal sites as well as bone-related biochemical
parameters and cytokines (each factor was considered as a separate
dependent variable in a series of models).The models were
adjusted for age, BMI and serum 25-hydroxy vitamin D levels.
Because the distributions of serum 25-hydroxy vitamin D, hs-
CRP, RANKL, osteocalcin, osteopontin and adipocytokines were
skewed, logarithmically transformed values were used for statistical
analysis. The geometric mean (standard deviation) for those
biochemical variables was provided.
Spearman correlation analysis was employed to study the
relationships among osteopontin, osteocalcin and T scores of
femoral neck.
All statistical analyses were performed using the PASW Statistics
GradPack 18 (SPSS Inc., Chicago, IL).
Results
The characteristics of the study participants are shown in
Table 1. There were no significant differences in age, gender,
weight, height, and BMI between the patients and the controls. Of
the total of 73 participants, 2 (5.7%) and 3 (7.9%) subjects were
smokers in the patient and control groups, respectively (p.0.05).
The median MS duration was 48.0 months (interquartile range,
12–84 months). The average EDSS score was 0.6260.49 (13
[37.1%] patients=0, 22 [62.9%] patients=1). All patients had
been administered pulse steroids at least once during the duration
of the disease. A total of 34 patients had been administered
immunomodulatory drugs (avonex=13, sinovex=9, rebif=7,
betaseron=5 subjects). Four (11.4%), two (5.7%), and eighteen
(51.4%) patients were on anticonvulsants, oral hypoglycaemic
agents, and vitamin D supplementation, respectively.
There were no statistically significant differences in serum levels
of 25-OH vitamin D levels between anticonvulsant drugs users and
non-users (median=24.68 nmol/l versus median=32.08 nmol/l,
p=0.196). Also, there were no statistically significant differences in
serum levels of 25-OH vitamin D levels between the MS patients
with vitamin D supplementation and the untreated patients
(median=37.52 nmol/l versus median=21.84 nmol/l, p=0.506).
The serum levels of bone-related cytokines, adipocytokines,
MMP-9, 25-OH vitamin D, hs-CRP, and the BMD measurements
of patients with MS and the healthy controls are also shown in
Table 1. There was no significant difference between the two
groups regarding hs-CRP, MMP-9, osteopontin, osteocalcin,
OPG, RANKL, and vaspin. There also was no significant
difference in the BMD measures between the two groups.
Although patients with MS had higher serum levels of omentin-
1 than the control group (Table 1), this difference was not
statistically significant.
BMI had a significant correlation with lumbar spine BMD
(r=0.49, p,0.0001), however, femoral neck BMD and other
bone- related biochemical markers were not correlated with BMI.
Table 2 shows the correlations for serum omentin-1 in relation
to age, BMI, biochemical, and BMD measures in MS patients and
controls. The serum omentin-1 levels were positively correlated
with osteopontin (b=0.48, p=0.012), osteocalcin (b=0.50,
p=0.006) and BMD at the femoral neck (b=0.45, p=0.011)
and total hip (b=0.43, p=0.015) in MS patients. In multiple
regression analysis, these correlations remained significant in MS
patients after adjustment for age, BMI and serum 25-OH vitamin
D levels (Table 2). Moreover, omentin-1 levels were positively
correlated with osteocalcin in MS patients and controls.
In multiple regression analysis, after adjustments, serum
omentin-1 showed no significant correlation with age and BMI
in MS patients and controls (Table 2).
No correlations were found between vaspin and age, BMI,
biochemical, and BMD measures in both groups (data not shown).
Serum levels of osteocalcin were significantly and positively
correlated with osteopontin levels in MS patients (r=0.61,
p,0.0001) and the controls (r=0.44, p=0.005). Both osteocalcin
(r=0.42, p=0.019) and osteopontin (r=0.49, p=0.008) were
correlated with T scores of femoral neck in patients with MS.
Discussion
Previous studies have described various adipo(cyto)kines that are
implicated in bone and adipose tissue crosstalk [3,4,21,22]. For
example, osteoclastogenesis is increased by adiponectin via the
RANKL/OPG mechanism, [4,21] and leptin is involved in the
control of bone mass by a complex mechanism that has an
important role in the central nervous system and osteoblastic b2-
adrenergic receptors [22]. However, there is a lack of studies on
the possible effects of omentin-1 on bone metabolism in the
medical literature.
In the current study, although no association could be found
between omentin-1 and BMD at multiple skeletal sites in the
healthy control group, we found, for the first time, that higher
circulating omentin-1is associated with higher BMD at the femoral
neck in patients with MS. As several lines of evidence indicate that
Table 1. Demographic, anthropometric, biochemical and
bone mineral density characteristics of MS patients and
healthy controls.
MS patients Controls P value
Age (years) 31.57 (7.26) 30.0 (6.12) 0.320
Gender (female/male) 27/8 30/8 0.852
Weight (kg) 61.08 (11.53) 66.0 (10.91) 0.066
Height (cm) 161.68 (8.83) 162.28 (7.98) 0.760
BMI (kg/m
2) 23.36 (4.03) 24.98 (3.19) 0.060
25-OH vitamin D (nmol/l) 32.35 (3.09)* 23.98 (2.13)* 0.087
hs-CRP (mg/ml) 1.11 (2.94)* 1.12 (3.01)* 0.286
RANKL (pg/ml) 2.07 (1.41)* 2.10 (1.59)* 0.815
OPG (pmol/l) 1.96 (0.90) 2.32 (0.90) 0.095
Osteopontin (ng/ml) 41.2 0 (2.35)* 37.67 (2.46)* 0.583
Osteocalcin (ng/ml) 1.62 (1.62)* 1.98 (1.88)* 0.446
MMP-9 (ng/ml) 20.65 (6.99)* 21.67 (3.59)* 0.413
Omentin-1 (ng/ml) 204.17 (2.01)* 191.86 (2.07)* 0.965
Vaspin (ng/ml) 1.58 (1.86)* 1.63 (1.94)* 0.774
Lumbar BMD (g/cm2) 0.964 (0.167) 1.028 (0.131) 0.072
Femur neck BMD (g/cm
2) 1.038 (0.196) 1.00 (0.102) 0.350
Total hip BMD (g/cm
2) 2.775 (0.573) 2.607 (0.424) 0.156
Values are means (standard deviation).
*Values are geometric means (standard deviation).
Abbreviations: BMI, body mass index; 25-OH vitamin D, 25-hydroxy vitamin D;
hs-CRP, high sensitive C-reactive protein; RANKL, the receptor activator of
nuclear factor-kB ligand; OPG, osteoprotegerin; MMP-9, matrix
metalloproteinase 9; BMD, bone mineral density.
doi:10.1371/journal.pone.0024240.t001
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adipocytokines in the immune system and autoimmune disorders
have been suggested [14], it could be hypothesized that complex
mechanisms might be involved in autoimmunity, omentin-1, and
bone metabolism in MS patients.
We found a significant correlation between omentin-1 and
osteopontin. Thus, osteopontin may be a possible candidate
biomarker in the crosstalk between bone and adipose tissue. This
pro-inflammatory cytokine is a multifunctional phosphorylated
acidic glycoprotein containing an arginine-glycine-aspartate inte-
grin binding motif that has been implicated in cell-mediated
immunity, inflammation, tissue repair, and cell survival [24,25].
Osteopontin may be produced by immune and non-immune cells
including bone cells [24,26]. The osteopontin level has been found
to be the most prominent expressed cytokine within MS lesions,
and increased plasma levels were reported in active relapsing-
remitting MS patients [27]. In a longitudinal study, OPN levels
were elevated prior to increased disease activity in relapsing-
remitting MS patients [28].
This cytokine and adhesion protein is essential for stress-
induced bone remodeling and bone strength because it attaches
bone cells to bone matrix and generates intracellular signals for
normal osteoclast motility on bone [24,29]. Recently, increased
serum osteopontin has been suggested as a biomarker for the early
diagnosis of osteoporosis in postmenopausal women. [29]. In
another recent study, increased osteopontin plasma levels in MS
patients correlated with the bone-specific degradation product C-
telopeptide of type-I collagen [30]. However, Altintas et al. [31],
by introducing osteopontin as a shared cytokine in the pathogen-
esis of MS and osteoporosis, reported lower levels of circulating
osteopontin in MS patients with osteoporosis at the femoral neck.
Similar to the latter study, we also found that serum osteopontin
levels were positively correlated with T-scores at the femoral neck.
Osteocalcin, an osteoblast-produced protein, is an important
mediator in the reciprocal relationship between bone metabolism
and adipocytes in glucose/fat metabolism. It has been associated
with measures of insulin resistance, the presence of metabolic
syndrome, and adipokine levels [32]. Osteocalcin can increase
beta-cell proliferation and insulin secretion as well as induce
adiponectin, an insulin-sensitizing adipokine, in adipocytes [2,33].
Interestingly, in the current study, osteocalcin levels were positively
correlated with omentin-1, osteopontin levels, and BMD at the
femoral neck in MS patients. Therefore, it seems that there are
complex mechanisms acting on BMD, osteopontin, osteocalcin,
and omentin-1 in the cross-talk between bone and adipose tissue in
MS patients. In fact, further studies are warranted in order to
elucidate the integrative mechanisms, which contribute in bone,
fat, and immunity interactions.
Matrix metalloproteinases (MMPs) are involved in the frag-
mentation of myelin basic protein and demyeliation in MS [34],
and MMP-9 serum levels are increased in relapses [35,36].
Because elevated serum levels of hs-CRP are associated with MS
relapses, hs-CRP may be a useful surrogate marker for detection of
subclinical inflammatory activity in MS [37]. We found no
relationship among MMP-9, hs-CRP, and omentin-1 in patients
with MS.
The relative concentration of RANKL and OPG in bone is a
major determinant of bone health [38]. The RANK/RANKL/
OPG system has also been shown to modulate dendritic cells and
activate T cells as well as to promote B-cell maturation and
antibody response, which suggests that this system plays an
important role in both skeletal and immune systems [39]. This
osteoimmunological system configures a wide range of molecular
and cellular interactions [40]. Kurban, et al., in a small study,
reported that RANKL and OPG levels were significantly higher in
MS patients compared with the healthy controls [41]. Thus, they
hypothesized that the RANK/RANKL/OPG system might be
involved in the immune induced mechanism of osteoclastogenesis
and bone loss in MS [41]. However, in the current study, there
were no significant differences in RANKL and OPG serum levels
Table 2. Multiple linear regression analysis for the association between omentin-1 (independent variable), and bone mineral
density, anthropometric measurements and biochemical parameters (dependent variables) in MS patients and healthy controls.
MS patients Controls
Unadjusted Adjusted* Unadjusted Adjusted*
b P value b P value b P value b P value
Age 20.37 0.044 20.35 0.060 20.14 0.380 20.14 0.409
BMI 20.03 0.871 0.01 0.946 20.01 0.964 0.02 0.880
25-OH vitamin D 0.03 0.851 0.12 0.552 20.05 0.730 20.04 0.816
hs-CRP 20.01 0.978 0.08 0.655 0.08 0.630 0.04 0.810
OPG 20.23 0.222 20.20 0.332 20.09 0.598 20.05 0.746
RANKL 0.10 0.572 0.08 0.697 20.04 0.772 20.05 0.760
MMP-9 0.01 0.978 0.04 0.813 20.26 0.116 20.27 0.110
Vaspin 20.03 0.863 20.06 0.768 0.04 0.801 0.03 0.859
Osteocalcin 0.50 0.006 0.53 0.004 0.37 0.021 0.35 0.036
Osteopontin 0.48 0.012 0.42 0.030 20.05 0.747 20.01 0.541
Lumbar BMD 0.01 0.791 0.01 0.965 0.15 0.360 0.14 0.382
Femur neck BMD 0.45 0.011 0.49 0.016 0.23 0.154 0.21 0.207
Total hip BMD 0.43 0.015 0.42 0.035 0.18 0.264 0.18 0.286
*Adjusted for age, BMI, and serum 25-OH vitamin D levels.
Abbreviations: BMI, body mass index; 25-OH vitamin D, 25-hydroxy vitamin D; hs-CRP, high sensitive C-reactive protein; RANKL, the receptor activator of nuclear factor-
kB ligand; OPG, osteoprotegerin; MMP-9, matrix metalloproteinase 9; BMD, bone mineral density.
doi:10.1371/journal.pone.0024240.t002
Omentin-1 in Multiple Sclerosis
PLoS ONE | www.plosone.org 4 September 2011 | Volume 6 | Issue 9 | e24240between MS patients and the controls. In addition, we found no
correlation among RANKL, OPG, and omentin-1 in MS patients.
It is interesting to note that serum levels of vaspin, a member of
the serine protease inhibitor family and an adipokine with insulin-
sensitizing effects, showed no correlations with BMD at different
skeletal sites, omentin-1, osteopontin, and osteocalcin in MS
patients. These results suggest that vaspin may not be involved in
the cross-talk between bone and adipose tissue in MS. However,
although there is a lack of studies on vaspin serum levels in relation
to bone metabolism including BMD, our findings also suggest that
different adipokines exert different influences on bone.
Patients with MS are at increased risk of osteoporosis and
fractures because they often have multiple risk factors for
osteoporotic fractures [42], reduced bone mass, and vitamin D
deficiency [43]. Low BMD is prevalent in patients with MS and is
related to the level of ambulatory function and physical activity
[44–46]. Overall, evidence exists that there are correlations
between EDSS with BMD at different skeletal sites [45–47]. Since
all patients in our study were ambulatory with low EDSS scores,
we did not find significant differences in BMD at different skeletal
sites between the patients with MS and the healthy controls.
There are several limitations to this study. First, the sample size
was small, which may have affected our statistical power. Second,
we did not include patients with high EDSS scores. All patients
were ambulatory and relatively young. Thus the results of the
study may not be generalized to nonambulatory individuals with
MS. However, evaluation of MS patients with low EDSS provided
us with a relatively good milieu to investigate early pathophysi-
ological changes in the osteoimmunology and adipose tissue.
Third, causality between omentin-1 and BMD could not be
clarified in our cross-sectional study. Since we assessed the
investigated adipocytokines with single measurements, the changes
in these adipocytokines over time could not be reflected in the
current study. To clarify circulating adipocytokines in relation to
worsening functional capacity and the duration of the disease,
longitudinal studies are warranted. The measurement of addition-
al adipocytokines and inflammatory markers and cytokines merits
consideration in order to elucidate the complex system that
regulates bone, fat, the immune system, and inflammation in MS.
A growing body of evidence supports that circulating vitamin D
levels may be involved in the regulation of the clinical disease
activity of MS and could be partially responsible for low bone
mineral density and the progression to osteoporosis in these
patients [44,48]. Low circulating vitamin D levels were reported in
MS patients [44].We also found low serum 25-OH vitamin D
levels among MS patients. However, more than half of those
patients were on vitamin D supplementation. It should be noted
that the control subjects in the current study also had low serum
25-OH vitamin D levels. In a multi-centre study in Iran, we
reported a high prevalence of moderate to severe vitamin D
deficiency among different urban areas [49].
Although circulating omentin-1 levels in relation to markers of
bone metabolism were adjusted for 25-OH vitamin D levels in
multiple regression models in MS patients and the controls, the
observed differences on correlation of bone markers/ omentin-1
between the two groups may be attributable rather to different
distribution of 25-OH vitamin D-status than the cohorts being MS
patients or controls per se.
In conclusion, elevated omentin-1 serum levels are correlated
with BMD at the femoral neck, and serum levels of osteocalcin and
osteopontin in MS patients. However, no correlations could be
found for vaspin, as an adipokine, in relation to BMD and bone
metabolism. The observed omentin-1 in relation to bone
metabolism in MS, as an autoimmune disorder, supports the
recent notion that adipose tissue has close cross-talk with bone and
the immune system as well as sharing an abundance of molecules
and regulatory mediators in complex mechanisms. The clarifica-
tion of this intermingled bone and adipocytokines complex system
in the osteoimmunology spectrum by integrative pathophysiolog-
ical approaches might promise attractive and novel pharmacolog-
ical insights for treatment of both osteoporosis and autoimmune
disorders such as MS in the future.
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